Precision For Medicine Acquires ProMedDx And GLAS Expert Biospecimen Companies

Pixabay License | Source:  Gerd Altmann , no changes made.
Advertisement

Precision for Medicine, part of Precision Medicine Group, has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space. With the acquisitions, Precision now offers an unmatched level of scientific understanding, high-quality specimen solutions, and global scale.

Founded in 2012, headquartered in Bethesda, Maryland, USA, Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with nearly 2,000 employees in 34 locations in the United States, Canada, and Europe.

Founded in 1998, located in Norton, Massachusetts, as a life science contract research organization (CRO), ProMedDx delivers the human biologics, the supporting clinical services, and the critical infrastructure that fuel scientific researchers in their discovery of novel biomarkers and commercialization in this era of precision medicine. ProMedDx’s patient-centered approach ensures clients’ priorities are served in the most efficient and quality focused manner available. The company envisages that a direct-to-patient connection holds greater promise and value to pharmaceutical, biotechnology, in-vitro diagnostics, and clinical research organizations worldwide.

Founded in 2015, GLAS is a medical pathology consulting firm and supplier of human biologics based in Winston-Salem, North Carolina. They serve corporate and academic entities invested in translational research activities. GLAS provides a clear pathway and focused vision for corporate entities investing in human biospecimen research.

The addition of ProMedDx and GLAS establishes an unrivaled biospecimen solutions platform within Precision, which operates one of the largest biorepositories in the world. ProMedDx is known throughout the diagnostics industry for its high-quality biofluid specimens; GLAS is a leader in tissue-based samples. With an expanded sourcing network and client base, along with an enhanced global laboratory infrastructure, Precision can effectively leverage its unique insight as a scientific solutions provider to supply clients with hand-selected, fit-for-purposes specimens for R&D, biomarker development, and companion diagnostics.

Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Combining two world-class biospecimen organizations, across all specimen types, Precision further enhances its abilities to enable life science innovators with scientifically robust services to accelerate the pace of discovery, development, and commercialization of biomarkers.

“Precision’s reputation as an expert in biomarker sciences is a real differentiator—having been in the specimen industry for over 20 years, I can attest there are no other companies that possess Precision’s level of scientific understanding or breadth of solutions. We are thrilled to be joining Precision and leveraging its translational and scientific expertise to deliver the highest quality solutions to the biopharmaceutical and diagnostic industry.” – Jim Boushell, co-founder, ProMedDx

“Clearly, the life sciences industry relies heavily upon medical and scientific insight. However, this expertise is often in short supply in biospecimen provision. It’s why we founded GLAS. By teaming up with Precision, we are able to expand this on-the-ground medical expertise to a highly advanced and expansive lab and clinical network—a hugely important distinction in the biospecimen industry.” – Dr. Cullen Taylor of GLAS

“We believe in the power of biomarkers to lead to novel, life-changing therapies, and we remain dedicated to providing unmatched scientifically grounded global services. By bringing ProMedDx and GLAS into the Precision family, we are proud to offer unparalleled, global biospecimens solutions while also expanding our footprint in the exploding Massachusetts and North Carolina biotechnology sectors.” – Chad Clark, President, Precision for Medicine

Sources

  1. https://www.prnewswire.com/news-releases/precision-for-medicine-launches-biospecimen-solutions-offering-with-acquisition-of-promeddx-and-glas-300894785.html
  2. https://www.linkedin.com/company/precision-for-medicine/about/
  3. https://www.promeddx.com/who-we-are/contact-us/
  4. https://www.linkedin.com/company/glas-/about/
Advertisement

David is a consultant/medical writer for a number of ongoing healthcare initiatives including for Athla LLC/ HealthLabs, a discovery automation company for Big Data leveraging Big Compute. He has a number of years experience in academic R&D and healthcare related projects including the fields of oncology and immunotherapy.